ARGNF:OTC-argenx SE (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 655.75

Change

+25.75 (+4.09)%

Market Cap

USD 36.93B

Volume

1.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJY UCB SA ADR

N/A

USD 36.22B
UCBJF UCB SA

N/A

USD 36.22B
GNMSF Genmab A/S

N/A

USD 13.91B
WXIBF WuXi Biologics

N/A

USD 10.26B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 9.12B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 8.24B
ZLDPF Zealand Pharma A/S

N/A

USD 8.01B
IVBIY IVBIY

N/A

USD 7.83B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.73B
AKESF Akeso, Inc.

N/A

USD 7.54B

ETFs Containing ARGNF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 76.75% 83% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 76.75% 82% B 89% A-
Trailing 12 Months  
Capital Gain 76.75% 83% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 76.75% 82% B 89% A-
Trailing 5 Years  
Capital Gain 411.35% 97% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 411.35% 97% N/A 95% A
Average Annual (5 Year Horizon)  
Capital Gain 25.41% 61% D- 67% D+
Dividend Return 25.41% 62% D 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 34.04% 85% B 67% D+
Risk Adjusted Return 74.65% 98% N/A 94% A
Market Capitalization 36.93B 100% F 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector